Chinook Therapeutics U.S., Inc. — Form D
Chinook Therapeutics U.S., Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2020-10-21. The offering totals $115.0M, of which $115.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-10-21
- Form: D
- Accession: 0001768185-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $115.0M
- Amount sold: $115.0M
- Investors: 25
- Date of first sale: 2020-08-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-378507
Issuer
- Name: Chinook Therapeutics U.S., Inc.
- CIK: 0001768185
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 1600 FAIRVIEW AVE. E., SEATTLE, WA, 98102
- Phone: 206-485-7051
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Srinivas Akkaraju | Director | Palo Alto, CA |
| Jeremy Caldwell | Director | Seattle, WA |
| Jerel Davis | Director | Alameda, CA |
| Eric Dobmeier | Director | Seattle, WA |
| Paul Eisenberg | Director | New York, NY |
| Preston Klassen | Director | Seattle, WA |
| Eric Dobmeier | Executive Officer | Seattle, WA |
| Tom Frolich | Executive Officer | Seattle, WA |
| Alan Glicklich | Executive Officer | Seattle, WA |
| Andrew King | Executive Officer | Seattle, WA |
| Srini Akkaraju | Director | Agoura Hills, CA |
| Sam Hall | Director | Seattle, WA |
Other filings by this issuer (1)
More